小児外科HP http://pedsurg.kpu-m.ac.jp/index.php
| 大学院科目名 | 小児外科学 | ||
| 医学部教室名 | 外科学教室（小児外科学部門） | ||
| スタッフ |
准教授 文野 誠久
講師 金 聖和
助教 井口 雅史
助教 井上 真帆
助教 永薮 和也
助教 髙山 勝平（北部）
病院助教 三村 和哉
病院助教 瀧本 篤朗
|
||
| 研究内容 |
研究内容
主な基礎研究
(1) 間葉系幹細胞を用いた神経芽腫のhoming効果および分化誘導療法
(2) 新規分子標的薬を用いた神経芽腫治療の前臨床試験
(3) 神経芽腫外科治療における転移巣の影響
(4) 先天性骨格筋欠損に対する再生医療の開発
(5) 胆道閉鎖症におけるマクロファージの役割と治療ターゲットとしての機能解析
主な臨床研究
(1) リンパ管腫に対するmTOR阻害剤の臨床効果
(2) 新生児先天性横隔膜ヘルニアの治療標準化に関する研究
(3) 短腸症候群の包括的治療戦略の構築
(4) 新たな低侵襲手術治療の開発
(5) 小児固形腫瘍に対する外科治療
|
||
| 研究業績 |
1) Kimura K, Kishida T, Wakao J, et al: Tumor-homingeffect of human mesenchymal stem cells in a TH-MYCN mouse model of neuroblastoma. J Pediatr Surg, 51: 2068-2073, 2016.
2) Wakao J, Kishida T, Fumino S, et al: Efficient direct conversion of human fibroblasts intomyogenic lineage induced by co-transduction with MYCL and MYOD1. Biochem BiophysRes Commun, 488: 368-373, 2017.
3) Takeuchi Y, Tanaka T, Higashi M, et al: In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma. J Pediatr Surg, 53: 2454-2459, 2018.
4) Maniwa J, Fumino S, Kimura K, et al: Novel mesenchymal stem celldelivery system as targeted therapy for neuroblastoma using the TH-MYCN mouse model. J Pediatr Surg, 54: 2600-2605, 2019.
5) Inoue M, Tsuchiya Y, Koike N, et al: Enhanced metastatic growth after local tumor resection in the presence of synchronous metastasis in a mouseallograft model of neuroblastoma. Pediatr Surg Int, 35, 1403–1411, 2019.
6) Takayama S, Sakai K, Fumino S, et al: An intra-amniotic injection of mesenchymal stem cells promotes lung maturity in a rat congenital diaphragmatic hernia model. Pediatr Surg Int, 35: 1353-1361, 2019.
7) Togashi T, Tanaka T, Takemoto M, et al: Anti-relapse effect of trametinib on alocal minimal residual disease neuroblastoma mouse model. J Pediatr Surg, 56: 1233-1239, 2021.
8) Takemoto M, Tanaka T, Tsuji R, et al: The synergistic antitumor effect ofcombination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma. Biochem Biophys ResCommun, 570: 41-46, 2021.
9) Kambe K, Iguchi M, Higashi M, et al: Development of minimallyinvasive cancer immunotherapy using anti–disialoganglioside GD2 antibody-producing mesenchymal stem cells forneuroblastoma mouse model. Pediatr Surg Int, 39: 43, 2022.
10) Sengoku Y, Higashi M, Nagayabu K, et al: IL13 and periostin in active fbrogenic areas of the extrahepatic bile ducts in biliary atresia patients. Pediatr Surg Int, 38: 1847-1853, 2022.
11) Iguchi M, Yagyu S, Kambe K, et al: Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy. Anticancer Res, 43: 2417-2424, 2023.
12) Mimura K, Fumino S, Yamashi K, et al: Systemic inflammationenhances metastatic growth in a syngeneic neuroblastoma mouse model. Pediatr Surg Int, 40: 195, 2024.
13) Shimamura A, Higashi M, Nagayabu K, et al: Stable two- and threedimensional cholangiocyte culture systems from extrahepatic bile ducts of biliary atresia patients: use of structural and functional bile duct epithelium models for in vitro analyses. Cytotechnology, 76: 415–424, 2024.
14) Nagano S, Fumino S, Kishida T, et al: Development of a skeletal muscle sheet with direct reprogramming-induced myoblasts on a nanogel-cross-linked porous freeze-dried gel scaffold in a mouse gastroschisis model. Pediat Surg Int, 40:241, 2024.
15) Suzuki K, Fumino S, Iguchi M, et al: Multidisciplinary therapeutic strategy with appropriate timing and modalities for treating cervicofacial lymphatic malformations in children. Pediatr Surg Int, 41:35, 2024.
16) Tsuji R, Tanaka T, Fumino S, et al: Combined MEK and YAPinhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease. J Pediatr Surg,2025, in press.
|
||
| 問い合わせ先 |
TEL：075-251-5809 |
||
| 教室独自のHP | http://pedsurg.kpu-m.ac.jp/index.php |
